表紙:経カテーテル僧帽弁修復装置の世界市場-2023年~2030年
市場調査レポート
商品コード
1352130

経カテーテル僧帽弁修復装置の世界市場-2023年~2030年

Global Transcatheter Mitral Valve Repair Devices Market - 2023-2030

出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.31円
経カテーテル僧帽弁修復装置の世界市場-2023年~2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

経カテーテル僧帽弁修復装置の世界市場は、そのダイナミクスに影響を与える様々な要因によって、長年にわたって著しい成長と変貌を遂げてきました。心血管疾患の増加、研究開発、医療機器への政府投資は、経カテーテル僧帽弁修復装置の世界市場に影響を与える主な要因の一つです。2020年の課題の後、経カテーテル僧帽弁修復装置産業は適度な回復力と適応力を示しました。

特に新興国における心血管疾患への政府投資は、経カテーテル僧帽弁端部修復(TEER)装置を引き続き促進し、世界の経カテーテル僧帽弁修復装置市場を押し上げると思われます。世界の経カテーテル僧帽弁修復装置業界は、僧帽弁逆流のより良い管理をますます重視しています。それぞれの取り組みには、僧帽弁閉鎖不全症治療のための環状形成術装置や経カテーテル僧帽弁形成術といった他の装置の使用が含まれます。

経カテーテルedge-to-edge修復(TEER)デバイスタイプは、市場シェアの半分以上を占めています。同様に、北米は経カテーテル僧帽弁修復装置市場を独占し、1/3以上の最大市場シェアを獲得しています。同地域の医療への急速な投資と経カテーテル僧帽弁修復装置市場における世界の主要企業の台頭により、最大の市場シェアホルダーとなっています。米国は消費者だけでなくメーカーも多いです。

ダイナミクス

研究者による研究開発の拡大

新興国は、所得水準の上昇、投資、インフラ整備に牽引され、医療分野の改善において急速な成長を遂げています。いくつかの国では、医療産業の拡大を反映し、経カテーテル僧帽弁修復装置に対する大きな需要が発生しています。研究開発の活発化は市場の成長を促進する重要な要因です。

最近の内科的治療や経カテーテル治療における改善により、二次性僧帽弁閉鎖不全症(SMR)治療の選択肢が大きく広がっています。機能的僧帽弁閉鎖不全症を伴う心不全患者に対するMitraClip経皮的治療の心血管アウトカム評価(COAPT)試験と呼ばれる重要な研究では、MitraClipシステムの第2バージョンを使用した僧帽弁経カテーテルedge-to-edge修復(M-TEER)が、LVEF(LV駆出率)とSMRが低下した心不全患者の予後とQOLを向上させることが実証されました。

問題のある僧帽弁(MV)の解剖学的構造におけるMRをさらに最小化し、手技の結果を改善するために、M-TEERの分野における現在の科学的進歩は、装置の設計を改善し、装置のサイズを大きくすることに焦点を当てています。これらの開発により、解剖学的課題からM-TEERの適応とならないSMR患者の心不全症状が軽減し、予後が改善する可能性があります。

資金調達や投資の増加

経カテーテル僧帽弁修復装置の世界市場の主な促進要因の1つは、特に新興国における堅調なパイプラインと、投資や資金調達の増加です。例えば、2022年11月23日、Nyra Medical, Inc.という医療機器企業が2,000万米ドルのシリーズA資金調達の完了を発表しました。同社は画期的な経カテーテル僧帽弁置換技術を開発しています。エピダレックス・キャピタル、ブロードビュー・ベンチャーズ、ジョージア・リサーチ・アライアンス・ベンチャー・ファンドが投資家として名を連ね、ベンサナ・キャピタルと国際的な大手医療機器企業が共同リードしました。

この資金調達の資金は、ナイラの技術を予備臨床試験でサポートするために利用されます。自然な弁の形状を維持しながら、僧帽弁逆流を引き起こす可能性のある不十分に対処するため、ナイラは、独自のインプラントを通じて本来の僧帽弁尖を変化させるCARLENと呼ばれる経カテーテル技術に取り組んでいます。

デバイスに関する課題と限界

様々な病因のMRに対しては、様々なアプローチを用いるべきです。すべてのMRの原因に対して、TEERには最も多くの調査データがあり、治療成功の最も説得力のある証明があります。環状動脈形成術を受けることができるのは二次性MRの患者だけですが、リーフレット修復術やより優れた進歩が期待されます。中心性後尖弁逸脱に対する索状突起修復術の有効性は、低リスクの患者のみを対象として検討されてきました。

TMVrは低侵襲の経大腿的方法であり、死亡率も低く、術後の回復も早いにもかかわらず、MVの病気や解剖学的構造の複雑さだけでなく、この方法のいくつかの欠点も否定できません。TMVrの主な欠点は、MRの低下が予測しにくく、継続または再発する可能性があることです。機能的MRを有する患者では、収縮期に修復装置がMVを部分的に閉塞させるなど、より多くの心臓リモデリングが起こるため、再発率が高くなる可能性があります。また、経カテーテル修復術は技術的に困難であることが多く、手技の有効性を保証するために様々なデバイスが必要となることもあります。

デバイスに関する合併症やリスク

経カテーテル心臓弁(THV)の固定力は、経カテーテル人工僧帽弁のフレームと周囲の組織との間の摩擦によって生み出されます。そのため、悪い場所での展開はこの力を低下させ、位置のずれや移動を引き起こす可能性があります。僧帽弁形成術を受けた連続23例のCheung TMVR症例研究では、1例の患者が心不全で再入院しました。

心エコー検査で、左房前方への5mmの弁移動が認められ、著しい弁間逆流を伴っていたため、2回目の何事もない経心尖弁的(TA)TMVRが必要となっています。Guerrero博士による僧帽弁輪石灰化(ViMAC)試験では、経カテーテル弁塞栓術(TVE)患者5人が2回目のTHVを必要とし、6人が植え込み器具の移動を経験したことが明らかになっています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 研究者による研究開発の拡大
      • 資金調達や投資の増加
    • 抑制要因
      • デバイスに関連する課題と限界
      • デバイスに関連する合併症やリスク
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 デバイスの種類別

  • 環状形成術デバイス
    • 直接環状形成術
    • 間接的環状形成術
  • 経カテーテルエッジ間修復(TEER)デバイス
  • 経カテーテル脊索修復術

第8章 適応症別

  • 僧帽弁閉鎖不全症(MR)
    • 一次性僧帽弁閉鎖不全症
    • 二次性僧帽弁閉鎖不全症
  • 僧帽弁狭窄症(MS)

第9章 エンドユーザー別

  • 病院
  • 専門クリニック
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Abbott
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Edwards Lifesciences Corporation
  • Cardiac Dimensions
  • NeoChord, Inc.
  • 4C Medical Technologies
  • Nyra Medical
  • Shockwave Medical Inc.
  • Coramaze Technologies
  • Boston Scientific Corporation
  • Medtronic

第13章 付録

目次
Product Code: MD6887

Overview

The global transcatheter mitral valve repair devices market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Rising cardiovascular disorders, research and development and government investments in medical devices are among the key drivers impacting transcatheter mitral valve repair devices globally. After the challenging year of 2020, the transcatheter mitral valve repair devices industry showed moderate resilience and adaptability.

Government investments in cardiovascular disorders, particularly in developing economies, will continue to drive transcatheter edge-to-edge repair (TEER) devices and boost the global transcatheter mitral valve repair devices market. The global transcatheter mitral valve repair devices industry is placing increasing emphasis on better management of mitral regurgitation. The respective initiatives includes the use of other devices, such as annuloplasty devices and transcatheter chordal repair for treatment of mitral regurgitation.

The transcatheter edge-to-edge repair (TEER) device type, accounts for over half of the market share. Similarly, the North America dominates the transcatheter mitral valve repair devices market, capturing the largest market share of over 1/3rd. The region's rapid investments in healthcare and rising major players in the transcatheter mitral valve repair devices market globally, makes it the largest market share holder. United States has the largest pool of manufacturers as well as consumers.

Dynamics

Growing Research and Development by the Researchers

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by rising income levels, investments and infrastructure development. Several countries have experienced substantial demand for transcatheter mitral valve repair devices, reflecting their expanding healthcare industries. Rising research and development will be a crucial factor driving the growth of the market.

Recent improvements in medical and transcatheter therapy have greatly expanded the options for treating secondary mitral regurgitation (SMR). An important study called the Cardiovascular Outcomes Evaluation of the MitraClip Percutaneous Therapy for Cardiac Failure Patients alongside Functional Mitral Regurgitation (COAPT) trial demonstrated that mitral valve transcatheter edge-to-edge repair (M-TEER) using the second version of the MitraClip system enhances prognosis as well as quality life expectancy in heart failure individuals who have reduced LV ejection fraction (LVEF) and SMR.

In order to further minimize MR and improve procedural outcomes in problematic mitral valve (MV) anatomies, current scientific advancement in the area of M-TEER focuses on improving device design and increasing device sizes. These developments might lead to a reduction in symptoms of heart failure and possibly a better prognosis for SMR patients who would not otherwise be eligible for M-TEER because of anatomic challenges.

Rising Number of Funding or Investments

One of the primary drivers of the global Transcatheter Mitral Valve Repair Devices market is robust pipeline, especially in emerging economies and rising investments and funding. For instance, on November 23, 2022, a medical device firm named Nyra Medical, Inc. has announced the completion of a $20 million Series A fundraising. The company is developing a revolutionary transcatheter mitral valve replacement technology. Epidarex Capital, Broadview Ventures, and the Georgia Research Alliance Venture Fund were among investors in the round, which was co-led by Vensana Capital and a significant, international medical equipment firm.

The financing's proceeds will be utilized to support Nyra's technology via preliminary clinical trials of viability. In order to address inadequacies that might otherwise result in mitral regurgitation while maintaining the natural valve shape, Nyra is working on a transcatheter technique called CARLEN that changes the native mitral valve leaflets through a proprietary implant.

Challenges and Limitations Associated with the Devices

For MR with various etiologies, various approaches should be used. For all MR causes, the TEER has the greatest research data and the most convincing proof of therapeutic success. Only individuals with secondary MR can receive an annuloplasty, however leaflet repair and more excellent advancements may be on the horizon. The effectiveness of chordal repair in treating central posterior leaflet prolapse has been examined exclusively in low-risk individuals; further research is required to support the efficacy, safety, and long-term effects of this procedure in high-risk patients.

Despite the minimally invasive transfemoral method, a low death rate, and rapid recovery following TMVr, several drawbacks of this strategy as well as the intricacy of MV illness and anatomy cannot be denied. TMVr's primary drawback is that MR decline is less predictable and could continue or recur. Recurrence rates may be higher in individuals who have functional MR because of more cardiac remodeling including the repair device's partial MV occlusion during systole. Transcatheter repair operations are also frequently technically difficult, and occasionally an array of devices is needed to guarantee the procedure's efficacy.

Complications or Risks Related to the Device

The anchoring force of the transcatheter heart valve (THV) is produced by friction between the transcatheter prosthetic mitral valve's frame and the surrounding tissue. As a result, deployment in a bad spot could reduce this force and cause misposition or migration. One patient was hospitalized again with heart failure in Cheung TMVR case study of 23 consecutive patients who underwent mitral ViV.

Echocardiography revealed 5-mm valve migration to the anterior left atrium with significant intervalvular regurgitation, necessitating a second uneventful transapical (TA) TMVR. Guerrero's valve-in-mitral annular calcification (ViMAC) study revealed that five transcatheter valve embolization (TVE) patients needed a second THV, and six patients experienced implanted device migration.

Segment Analysis

The global transcatheter mitral valve repair devices market is segmented based on device type, indication, end user and region.

High Advantages and Advancements of Transcatheter Edge-to-Edge Repair Devices

A minimally invasive treatment called mitral transcatheter edge-to-edge repair (TEER) is used to treat mitral valve regurgitation, a disease where the valve between the left chambers of the heart doesn't seal completely. Each time the heart beats, healthy heart valves securely open and close to regulate blood flow from the heart and back to the other parts of the body. Blood seeps backward if the mitral valve isn't closing properly, which makes the heart work harder. People may feel exhausted or out of breath as a result of a buildup of pressure in the lungs. In the absence of medical care, the regurgitation (backflow) may develop over time and manifest new symptoms.

In TEER, a tiny device is implanted in the valve to aid in its more complete closure and the restoration of regular blood flow utilizing either the Pascal Precision or Abbott MitraClip systems. These tools function by bringing the flaps of the valve into a more straight-forward alignment. They are put through an artery using a catheter, which is a long, thin tube. As a result, only a little incision is needed for the treatment. Feeling short of breath, chest pain, and other symptoms can be reduced thanks to TEER, which also enhances quality of life.

Geographical Penetration

North America Accounted for Largest Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for transcatheter mitral valve repair devices in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for transcatheter mitral valve repair devices.

Increasing expenditure on healthcare and rising research studies, advancement of technologies for different devices for mitral regurgitation, and increase in pharmaceutical and medical devices business establishment across the region are also contributing to the growth of transcatheter mitral valve repair devices market share of this region.

The key healthcare organizations' and businesses' joint research initiatives are also expected to contribute to the rising demand, as will new product development, which constantly looks to improve present options. The market in this area is growing as people become more aware of various novel devices such as annuloplasty devices, for treatment purposes. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global transcatheter mitral valve repair devices market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising cardiovascular disorders have fueled the demand for transcatheter mitral valve repair devices in the region. United States have been proactive in executing several initiatives or researches, stimulating transcatheter mitral valve repair devices demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global transcatheter mitral valve repair devices market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the medical device sector, with a significant consumer of transcatheter mitral valve repair devices, was significantly impacted.

Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020. Major pharmaceutical or medical device industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for transcatheter mitral valve repair devices. As a result, many medical device plants either suspended or reduced production to align with the reduced demand.

The COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials to the pharmaceuticals manufacturing plants. Movement limitations and border closures caused production and supply delays. Additionally, some nations experienced a lack of raw resources as a result of supply chain network interruptions.

With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages as workers fell sick or were unable to travel to work due to lockdown restrictions. To curb the spread of the virus, pharmaceutical plants implemented stringent safety measures, reducing the number of workers allowed on-site at a time. However, these measures were vital to safeguard the health of the workforce and maintain essential operations during the pandemic.

Russia-Ukraine War Impact Analysis

The medical device businesses are starting to worry regarding their capacity to continue operating, much like other parts of the world. Russia's invasion of Ukraine has an effect on millions of people not only in this nation in Eastern Europe but also all around the world. Device developers will thus experience delays in the development process, a loss of business consistency, and the possibility of non-compliance for drugs already on the market.

For many years, clinical trials in several therapeutic fields have benefited significantly from the participation of Ukraine, Russia, and other CIS nations. Clinical trial durations can frequently be accelerated by incorporating more patients into studies when there is availability to skilled investigators, high-quality patient populations, and big patient populations. Trials that are delayed in Russia and Ukraine as well as relocation to other regions of Europe for fresh trials are currently viable choices. These factors will impact the global transcatheter mitral valve repair devices market.

By Device Type

  • Annuloplasty Devices
    • Direct Annuloplasty
    • Indirect Annuloplasty
      • Transcatheter Edge-to-Edge Repair (TEER) Devices
      • Transcatheter Chordal Repair

By Indication

  • Mitral regurgitation (MR)
  • Primary Mitral Regurgitation
  • Secondary Mitral Regurgitation
    • Mitral Stenosis (MS)

By End User

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On September 17, 2022, results from CLASP IID, a groundbreaking controlled, randomized study that directly contrasts two cutting-edge transcatheter edge-to-edge repair (TEER) procedures, were released by Edwards Lifesciences Corporation. According to the study, TEER is a safe and efficient treatment option for those having degenerative mitral regurgitation (DMR). Findings from the CLASP IID essential trial were concurrently published in JACC: Cardiovascular Interventions and offered as a late-breaking clinical research meeting at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the yearly scientific conference of the Cardiovascular Research Foundation.
  • On June 8, 2022, MitraClip, the first transcatheter edge-to-edge repair (TEER) device in the world, and TriClip, a pioneering minimally invasive tricuspid heart valve repair technology, both received late-breaking data announcements from Abbott. The statistics support the structural cardiac solutions offered by the company's for mitral as well as tricuspid regurgitation (MR or TR) in a wide spectrum of patient populations struggling with leaky heart valves.

Competitive Landscape

The major global players in the market include Abbott, Edwards Lifesciences Corporation, Cardiac Dimensions, NeoChord, Inc., 4C Medical Technologies, Nyra Medical, Shockwave Medical Inc., Coramaze Technologies, Boston Scientific Corporation and Medtronic among others.

Why Purchase the Report?

  • To visualize the global transcatheter mitral valve repair devices market segmentation based on device type, indication, end user and region as well as understand key commercial assets and players
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of transcatheter mitral valve repair devices market-level with all segments
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study
  • Product mapping available as excel consisting of key products of all the major players

The global transcatheter mitral valve repair devices market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Device Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Research and Development by the Researchers
      • 4.1.1.2. Rising Number of Funding or Investments
    • 4.1.2. Restraints
      • 4.1.2.1. Challenges and Limitations Associated with the Devices
      • 4.1.2.2. Complications or Risks Related to the Device
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Device Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 7.1.2. Market Attractiveness Index, By Device Type
  • 7.2. Annuloplasty Devices*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Direct Annuloplasty
    • 7.2.4. Indirect Annuloplasty
  • 7.3. Transcatheter Edge-to-Edge Repair (TEER) Devices
  • 7.4. Transcatheter Chordal Repair

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Mitral regurgitation (MR)*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Primary Mitral Regurgitation
    • 8.2.4. Secondary Mitral Regurgitation
  • 8.3. Mitral Stenosis (MS)

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Abbott*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Edwards Lifesciences Corporation
  • 12.3. Cardiac Dimensions
  • 12.4. NeoChord, Inc.
  • 12.5. 4C Medical Technologies
  • 12.6. Nyra Medical
  • 12.7. Shockwave Medical Inc.
  • 12.8. Coramaze Technologies
  • 12.9. Boston Scientific Corporation
  • 12.10. Medtronic

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us